Literature DB >> 32584606

Delayed contrast dynamics as marker of regional impairment in pulmonary fibrosis using 5D MRI - a pilot study.

Maria Ta Buzan1,2,3,4, Andreas Wetscherek5,6, Christopher M Rank5, Michael Kreuter3,7, Claus Peter Heussel1,3,7, Marc Kachelrieß5, Julien Dinkel1,8,9.   

Abstract

OBJECTIVE: To analyse delayed contrast dynamics of fibrotic lesions in interstitial lung disease (ILD) using five dimensional (5D) MRI and to correlate contrast dynamics with disease severity.
METHODS: 20 patients (mean age: 71 years; M:F, 13:7), with chronic fibrosing ILD: n = 12 idiopathic pulmonary fibrosis (IPF) and n = 8 non-IPF, underwent thin-section multislice CT as part of the standard diagnostic workup and additionally MRI of the lung. 2 min after contrast injection, a radial gradient echo sequence with golden-angle spacing was acquired during 5 min of free-breathing, followed by 5D image reconstruction. Disease was categorized as severe or non-severe according to CT morphological regional severity. For each patient, 10 lesions were analysed.
RESULTS: IPF lesions showed later peak enhancement compared to non-IPF (severe: p = 0.01, non-severe: p = 0.003). Severe lesions showed later peak enhancement compared to non-severe lesions, in non-IPF (p = 0.04), but not in IPF (p = 0.35). There was a tendency towards higher accumulation and washout rates in IPF compared to non-IPF in non-severe disease. Severe lesions had lower washout rate than non-severe ones in both IPF (p = 0.003) and non-IPF (p = 0.005). Continuous contrast agent accumulation, without washout, was found only in IPF lesions.
CONCLUSIONS: Contrast agent dynamics are influenced by type and severity of pulmonary fibrosis, which might enable a more thorough characterisation of disease burden. The regional impairment is of particular interest in the context of antifibrotic treatments and was characterised using a non-invasive, non-irradiating, free-breathing method. ADVANCES IN KNOWLEDGE: Delayed contrast enhancement patterns allow the assessment of regional lung impairment which could represent different disease stages or phenotypes in ILD.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32584606      PMCID: PMC7465850          DOI: 10.1259/bjr.20190121

Source DB:  PubMed          Journal:  Br J Radiol        ISSN: 0007-1285            Impact factor:   3.039


  26 in total

1.  Combination of signals from array coils using image-based estimation of coil sensitivity profiles.

Authors:  M Bydder; D J Larkman; J V Hajnal
Journal:  Magn Reson Med       Date:  2002-03       Impact factor: 4.668

2.  Quantitative study of the difference in pulmonary perfusion in different respiratory phases in healthy volunteers.

Authors:  Shoji Yoshida; Dong Wu; Mitsutaka Fukumoto; Naoki Akagi; Harumichi Seguchi
Journal:  Ann Nucl Med       Date:  2002-12       Impact factor: 2.668

3.  Nintedanib and pirfenidone. New antifibrotic treatments indicated for idiopathic pulmonary fibrosis offer hopes and raises questions.

Authors:  Ganesh Raghu; Moisés Selman
Journal:  Am J Respir Crit Care Med       Date:  2015-02-01       Impact factor: 21.405

4.  T2 mapping of CT remodelling patterns in interstitial lung disease.

Authors:  Maria T A Buzan; Monika Eichinger; Michael Kreuter; Hans-Ulrich Kauczor; Felix J Herth; Arne Warth; Carmen Monica Pop; Claus Peter Heussel; Julien Dinkel
Journal:  Eur Radiol       Date:  2015-06-03       Impact factor: 5.315

5.  Self-gated radial MRI for respiratory motion compensation on hybrid PET/MR systems.

Authors:  Robert Grimm; Sebastian Fürst; Isabel Dregely; Christoph Forman; Jana Maria Hutter; Sibylle I Ziegler; Stephan Nekolla; Berthold Kiefer; Markus Schwaiger; Joachim Hornegger; Tobias Block
Journal:  Med Image Comput Comput Assist Interv       Date:  2013

6.  Prediction of pulmonary hypertension in patients with or without interstitial lung disease: reliability of CT findings.

Authors:  Esam H Alhamad; Ahmad A Al-Boukai; Feisal A Al-Kassimi; Hussam F Alfaleh; Mostafa Q Alshamiri; Abdulaziz H Alzeer; Hadil A Al-Otair; Gehan F Ibrahim; Shaffi A Shaik
Journal:  Radiology       Date:  2011-05-25       Impact factor: 11.105

7.  Proton magnetic resonance imaging to stage activity of interstitial lung disease.

Authors:  R G McFadden; T J Carr; T E Wood
Journal:  Chest       Date:  1987-07       Impact factor: 9.410

Review 8.  Interstitial lung disease.

Authors:  Vincent Cottin
Journal:  Eur Respir Rev       Date:  2013-03-01

9.  3-T MRI for differentiating inflammation- and fibrosis-predominant lesions of usual and nonspecific interstitial pneumonia: comparison study with pathologic correlation.

Authors:  Chin A Yi; Kyung Soo Lee; Joungho Han; Man Pyo Chung; Myung Jin Chung; Kyung Min Shin
Journal:  AJR Am J Roentgenol       Date:  2008-04       Impact factor: 3.959

10.  Regional Lung Ventilation Analysis Using Temporally Resolved Magnetic Resonance Imaging.

Authors:  Christoph Kolb; Andreas Wetscherek; Maria Teodora Buzan; René Werner; Christopher M Rank; Marc Kachelrie; Michael Kreuter; Julien Dinkel; Claus Peter Heuel; Klaus Maier-Hein
Journal:  J Comput Assist Tomogr       Date:  2016 Nov/Dec       Impact factor: 1.826

View more
  1 in total

1.  Dynamic contrast-enhanced magnetic resonance imaging of the lung reveals important pathobiology in idiopathic pulmonary fibrosis.

Authors:  Sydney B Montesi; Iris Y Zhou; Lloyd L Liang; Subba R Digumarthy; Sarah Mercaldo; Nathaniel Mercaldo; Ravi T Seethamraju; Bruce R Rosen; Peter Caravan
Journal:  ERJ Open Res       Date:  2021-11-08
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.